STANDARDIZATION OF MODEL OF INDUCTION OF HEPATOTOXICITY WITH ANTI-TUBERCULOSIS DRUGS IN WISTAR ALBINO RATS
DOI:
https://doi.org/10.22159/ajpcr.2017.v10i6.11971Keywords:
PharmacologyAbstract
Objective: The objective of the study to standardize the model of hepatotoxicity induced by ATT drugs in Wistar Albino rats. Isoniazid (INH), rifampicin (RMP), pyrazinamide (PZA), the first line drugs used in the treatment of tuberculosis (TB) associated with the potential adverse effect. Numerous animal studies were reported endeavoring induction and cure of anti-TB (ATT) drug-induced hepatotoxicity using herbal and chemical drugs. However, the previous reported study failed to replicate where Wistar albino rats were treated with INH, RMP, and PZA and had shown the significant development of liver injury. Hence in present paper, aimed to develop a standardize model of induction of hepatotoxicity with ATT drugs.
Methods: Wistar rats were treated with ATT drugs in combination in various doses up to 4-8 weeks. Total nine experiments were conducted to achieve successful hepatotoxicity. The aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) were the biochemical parameters of assessment. Histopathological changes in the liver were also examined.
Results: No evidence of any liver injury or an inflammatory infiltrate has been observed as had been reported in the previous studies. Rather decrease in serum ALT levels has been observed by researcher. In short, hepatic injury cannot be developed with the doses used in previous reported papers. The successful attempt to induce hepatotoxicity can be achieved with the doses of INH - 100, RMP - 300, PZA - 700 mg/kg. The findings were confirmed by the raised ALT, AST, and ALP levels compared with baseline. The histopathological changes also support the findings.
Conclusion: The dose of INH - 100, RMP – 300 and PZM - 700 mg/kg. Succeeds to induce hepatotoxicity in Wistar albino rats and Swiss albino mice as well.
Downloads
References
Raviglione MC, Snider DE Jr, Kochi A. Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic. JAMA 1995;273(3):220-6.
World Health Organization. Global Tuberculosis Control: Surveillance, Planning, Financing. WHO Report; 2002. p. 237. Available from: http://www.popline.org/node/237595.
Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest 1991;99(2):465-71.
Chan ED, Iseman MD. Current medical treatment for tuberculosis. BMJ 2002;325(7375):1282-6.
Mahashur AA, Prabhudesai PP. Hepatitis and antitubercular therapy. J Assoc Physicians India 1991;39(8):595-6.
Ika FB, Erna KS. Decrease of liver function after treatment of antituberculosis drugs in tuberculosis patients with malnutrition and alcohol consumption Int J Pharm Pharm Sci 2016;8(7):269-73.
Siddiqui S, Mirza MA, Jaffer S, Ansari SF. Study on prevalence of adverse drug reactions in patients suffering from tuberculosis in a tertiary care hospital. Int J Pharm Pharm Sci 2016;8(8):375-7.
Vijaya PV, Suja V, Devi CS. Hepatoprotective effect of liv.52 on antitubercular drug-induced hepatotoxicity in rats. Fitoterapia 1998;LXIX:520-3.
Funde SK, Jaju JB, Dharmadhikari SC, Pawar GR. Effect of Lagenaria siceraria fruit extract (Bottle gourd) on hepatotoxicity induced by antitubercular drugs in albino rats. Int J Basic Clin Pharmacol 2013;2(6):728-34.
Samuel AJ, Mohan S, Chellappan DK, Kalusalingam A, Ariamuthu S. Hibiscus vitifolius (Linn.) root extracts shows potent protective action against anti-tubercular drug induced hepatotoxicity. J Ethnopharmacol 2012;141(1):396-402.
Kale BP, Kothekar MA, Tayade HP, Jaju JB, Mateenuddin M. Effect of aqueous extract of Azadirachta indica Leaves on hepatotoxicity induced by antitubercular drugs in rats. Indian J Pharmacol 2003;35:177-80.
Gamble M. The hematoxylins and eosin. In: Bancroft JD, Gamble M, editors. Theory and Practice of Histological Techniques. 6th ed. London: Churchill Livingstone Elsevier; 2008. p. 121-4.
Jaeschke H, Gores GJ, Cederbaum AI, Hinson JA, Pessayre D, Lemasters JJ. Mechanisms of hepatotoxicity. Toxicol Sci 2002;65(2):166-76.
Mehta S. Malnutrition and drugs: Clinical implications. Dev Pharmacol Ther 1990;15(3-4):159-65.
Pande JN, Singh SP, Khilnani GC, Khilnani S, Tandon RK. Risk factors for hepatotoxicity from antituberculosis drugs: A case-control study. Thorax 1996;51(2):132-6.
Ostapowicz G, Fontana RJ, Schiødt FV, Larson A, Davern TJ, Han SH, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002;137(12):947-54.
Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. An official ATS statement: Hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006;174(8):935-52.
Sodhi CP, Rana SV, Mehta SK, Vaiphei K, Attri S, Thakur S, et al. Study of oxidative stress in isoniazid-induced hepatic injury in young rats with and without protein-energy malnutrition. J Biochem Toxicol 1996;11(3):139-46.
Metushi IG, Cai P, Zhu X, Nakagawa T, Uetrecht JP. A fresh look at the mechanism of isoniazid-induced hepatotoxicity. Clin Pharmacol Ther 2011;89(6):911-4.
Hussain Z, Kar P, Husain SA. Antituberculosis drug-induced hepatitis: Risk factors, prevention and management. Indian J Exp Biol 2003;41(11):1226-32.
Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: Concise up-to-date review. J Gastroenterol Hepatol 2008;23(2):192-202.
Sarma GR, Immanuel C, Kailasam S, Narayana AS, Venkatesan P. Rifampin-induced release of hydrazine from isoniazid. A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin. Am Rev Respir Dis 1986;133(6):1072-5.
Whitehouse LW, Lodge BA, By AW, Thomas BH. Metabolic disposition of pyrazinamide in the rat: Identification of a novel in vivo metabolite common to both rat and human. Biopharm Drug Dispos 1987;8(4):307-18.
Lacroix C, Hoang TP, Nouveau J, Guyonnaud C, Laine G, Duwoos H, et al. Pharmacokinetics of pyrazinamide and its metabolites in healthy subjects. Eur J Clin Pharmacol 1989;36(4):395-400.
Metushi IG, Nakagawa T, Uetrecht J. Direct oxidation and covalent binding of isoniazid to rodent liver and human hepatic microsomes: Humans are more like mice than rats. Chem Res Toxicol 2012;25(11):2567-76.
O’Brien PJ, Slaughter MR, Polley SR, Kramer K. Advantages of glutamate dehydrogenase as a blood biomarker of acute hepatic injury in rats. Lab Anim 2002;36(3):313-21.
Ng W, Lobach AR, Zhu X, Chen X, Liu F, Metushi IG, et al. Animal models of idiosyncratic drug reactions. Adv Pharmacol 2012;63:81-135.
Mehmedagic A, Vérité P, Ménager S, Tharasse C, Chabenat C, André D, et al. Determination of pyrazinamide and its main metabolites in rat urine by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1997;695(2):365-72.
Stout JE, Engemann JJ, Cheng AC, Fortenberry ER, Hamilton CD. Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis. Am J Respir Crit Care Med 2003;167(6):824-7.
Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003;167(11):1472-7.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
